Metastatic NSCLC with Corey J. Langer, MD, David Spigel, MD, Denise O'Dea, NP, and Jack West, MD: Case 2 - Episode 10
What are the options for treatment access and reimbursement in this patient?
For this sort of individual who works in physical therapy, presumably she is employed by an institution and not freelancing. She should have insurance. She is from Brooklyn, which last I checked does have access to care for those who aren’t typically obtaining insurance from employers. In this regard, geography, to some extent, is destiny. But most commercial payers will cover, to a large extent, the cost of these agents.
Of course, the co-pays at times can be onerous and there are programs initiated by specific companies that help cover at least part of the co-pay, so that the dollar amounts, the expenditures, are not too high for individuals. The goal, of course, is to keep patients on these agents and, in some cases, they may need to stay on these agents not just months but several years. If there’s a financial [burden with] the treatment, that will potentially compromise any therapeutic benefit they might obtain.
CASE 2: mNSCLC
Sarah W. is a 58-year old physical therapist from Brooklyn, New York who is also active in a community theater group; her prior medical history is notable for mild GERD controlled with diet and proton pump inhibitor, and hyperlipidemia, controlled with atorvastatin.
She has a 12-pack-year smoking history but quit about 20 years ago after developing a severe respiratory infection. After showing chest x-ray abnormalities on a routine visit to her PCP, she is referred for further evaluation.
Her initial CT scan shows multiple bilateral lung nodules, a large 8-cm mass in the left upper lobe (LUL), suspicious for malignant pleural effusion, and several hepatic nodules
Transbronchial biopsy of the LUL mass shows adenocarcinoma T3 (based on size); biopsy of the hepatic nodules was consistent with metastatic disease, and she was deemed unresectable on surgical consult
Mutational status was reported asEGFRexon 21 (L858R) substitution; no other actionable mutations detected
At the time of diagnosis the patients performance status is 0
Sarah wishes to continue with her normal work schedule and rehearsals for an upcoming community theater production. Her oncologist initiates her on afatinib 40 mg/day.
At her 2-week follow-up, she shows symptoms of increasing diarrhea (≥6 stools/day), which has not improved with antidiarrheals, and a papular rash on her upper arms
Rash is not very itchy or bothersome, however, diarrhea interferes with both her work schedule and rehearsals
Diet modifications and loperamide are recommended for diarrhea, and topical corticosteroids for her rash; she continues therapy at 40 mg/day
At 3 months, while other symptoms have begun to improve, she shows symptoms of gingival stomatitis, and the nursing team recommends diet modifications and a mouth rinse as needed; she continues therapy at 40 mg/day
At her next follow-up, CT scan shows stable disease, with shrinkage in the primary mass and no new hepatic nodules.
Her diarrhea has improved to grade 1 with loperamide and diet; stomatitis and rash have been effectively managed with prior recommendations